United States · FDA National Drug Code directory
Bexsero
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 58160-976_db17d990-e6e2-450c-b9ed-923ec92df84d
- Product NDC
- 58160-976
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- NEISSERIA MENINGITIDIS SEROGROUP B NHBA FUSION PROTEIN ANTIGEN, NEISSERIA MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN ANTIGEN and NEISSERIA MENINGITIDIS SEROGROUP B NADA PROTEIN ANTIGEN
- Labeler
- GlaxoSmithKline Biologicals SA
- Marketing category
- BLA
- Marketing start / end (source format)
- 20161201
- Source listing expiry
- 20261231
Source-listed ingredients
- NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN — 50 ug/.5mL
- NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN — 50 ug/.5mL
- NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN — 50 ug/.5mL
- NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE ANTIGEN — 25 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE in 1 CARTON (58160-976-20) / .5 mL in 1 SYRINGE (58160-976-02) · 58160-976-20
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →